Prospective Randomized Open Label Comparative Study of Efficacy of Atorvastatin Alone and Atorvastatin with Omega 3 Fatty Acids in Patients with Dyslipidaemia Attending Tertiary Care Hospital
International Journal of Current Pharmaceutical Review and Research · 30.04.2026 · 18 (04)
DOI: 10.25258/ijcpr.18.4.201 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.04.2026. Verfasst von Neha Fatima und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Dyslipidaemia is an important modifiable cardiovascular risk factor which is highly prevalent in the Indian population. Atorvastatin reduces low-density lipoprotein cholesterol (LDL-C), but a large proportion of patients have elevated triglycerides and residual cardiovascular risk. Omega-3 fatty acids have been demonstrated to lower triglycerides, and may offer added benefit when used in combination with statins.
Methods
This prospective, open-label, randomized comparative study was carried out between February 2020 to August 2021 at a tertiary care hospital- Aryabhatta. One hundred dyslipidaemia patients were assigned to either Group A (atorvastatin 10–20 mg once daily) or Group B (atorvastatin 10–20 mg + omega-3 fatty acids 1 g twice daily) with a random allocation. Treatment duration was 12 weeks. Lipid profiles were evaluated at baseline, 6 weeks and 12 weeks. Statistical analysis was conducted with SPSS, and p < 0.05 was considered statistically significant.
Results
There was a statistically significant improvement among the study and control groups in the 12 weeks for all lipid parameters (p < 0.001). The combination therapy group also showed much decreased triglycerides and slightly increased high-density lipoprotein cholesterol (HDL-C) as compared to atorvastatin monotherapy. Both groups had a significant reduction in LDL-C, which was slightly greater in the combination group. Tolerability of both regimens was good with minimal adverse effects.
Conclusion
Atorvastatin plus omega-3 fatty acids was more effective than atorvastatin alone, especially in the reduction of triglycerides and similarly safe. Combination therapy can help in the management of patients with mixed dyslipidaemia; however, large multicentric trials are required to determine long-term cardiovascular outcomes.
Zitieren
APA
Fatima, N., Kishor, A., Sinha, R. I., Sinha, K. K., & Alam, M. E. (2026). Prospective Randomized Open Label Comparative Study of Efficacy of Atorvastatin Alone and Atorvastatin with Omega 3 Fatty Acids in Patients with Dyslipidaemia Attending Tertiary Care Hospital. International Journal of Current Pharmaceutical Review and Research, 18(04). https://doi.org/10.25258/ijcpr.18.4.201
Vancouver
Fatima N, Kishor A, Sinha RI, Sinha KK, Alam ME. Prospective Randomized Open Label Comparative Study of Efficacy of Atorvastatin Alone and Atorvastatin with Omega 3 Fatty Acids in Patients with Dyslipidaemia Attending Tertiary Care Hospital. International Journal of Current Pharmaceutical Review and Research. 2026;18(04). doi:10.25258/ijcpr.18.4.201
BibTeX
@article{Fatima2026,
author = {Fatima, Neha and Kishor, Ajit and Sinha, Rani Indira and Sinha, Keshav Kumar and Alam, Md Ejaz},
title = {Prospective Randomized Open Label Comparative Study of Efficacy of Atorvastatin Alone and Atorvastatin with Omega 3 Fatty Acids in Patients with Dyslipidaemia Attending Tertiary Care Hospital},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {04},
doi = {10.25258/ijcpr.18.4.201}
}
EUVIMED